Drug-labels.com

Teva-Dabigatran: Uses, Side Effects and Dosage

Status:
Prescription (Rx) Current status: Cancelled Pre Market Facts
Strength:
75 mg, 150 mg

Patient Medication Information: uses, side effects, how to take - Teva-Dabigatran

ABOUT THIS MEDICATION

What the medication is used for:

TEVA-DABIGATRAN is a blood thinner (prevents blood clots from forming).

TEVA-DABIGATRAN is prescribed:

-After knee or hip replacement surgery to prevent the formation of blood clots in the vein of your leg(s) or in your lung(s).

-To treat blood clots and prevent them from re-occurring in the veins of your legs and/or lungs.

If blood clots form in the veins of your legs you are at risk of a blood clot dislodging and traveling to the lungs causing serious health risks.

-To people who have irregular heartbeats (atrial fibrillation) to prevent a stroke (damage to part of the brain caused by an interruption of its blood supply), or sudden blocking of a blood vessel by a blood clot. People with atrial fibrillation have a part of their heart that does not beat the way it should. This can lead to formation of blood clots which increases the risk of stroke.

What it does:

TEVA-DABIGATRAN helps prevent the formation of blood

clots by blocking the activity of a protein called thrombin.

When it should not be used:

Do not take TEVA-DABIGATRAN if you:

  • Have severely reduced kidney function or your kidneys do not function.
  • Have active bleeding or bleed excessively.
  • Have a disease that increases your chances of bleeding, or bleeding in the brain (stroke) within the last 6 months or recent bleeding of a stomach ulcer.
  • Have an epidural or spinal catheter in place or within the first two hours after its removal.

    Your doctor will know what precautionary

    measures are required. TEVA-DABIGATRAN is not recommended for patients receiving epidural pain control after surgery.

  • Are taking oral ketoconazole, used to treat fungus infection.
  • Are already taking another blood thinner, including apixaban (ELIQUIS), bivalirudin, dalteparin, enoxaparin, fondaparinux, rivaroxaban (XARELTO), unfractionated heparin, warfarin (COUMADIN), unless your physician has decided to switch you to or from TEVA-DABIGATRAN.
  • Have an artificial heart valve.
  • Are breastfeeding. It is possible that TEVA-DABIGATRAN passes into breast milk.

  • Are allergic to dabigatran etexilate, dabigatran, or any other ingredient in the formulation.

What the medicinal ingredient is:

Dabigatran etexilate, as dabigatran etexilate mesilate.

What the non-medicinal ingredients are:

tartaric acid pellets, hydroxypropyl cellulose, hypromellose, isopropyl alcohol, talc and titanium dioxide. HPMC Capsule shell composition:

Hypromellose, titanium dioxide

75 mg and 150 mg: carrageenan, FD&C blue 2/indigo carmine and potassium chloride.

Imprinting composition (black Ink): ammonia solution, black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac.

What dosage forms it comes in:

Capsules: 75 mg and 150 mg

WARNINGS AND PRECAUTIONS

Stopping early any blood thinner, including

TEVA-DABIGATRAN, increases the risk of having a sudden blocking of a blood vessel by a blood clot. This can lead to death or severe injury. If you need to stop TEVA-DABIGATRAN, your doctor may give you another blood thinner.

You may bleed very seriously or severely in any part of your body while you are taking TEVA-DABIGATRAN.

In order to help prevent serious bleeding with TEVA-DABIGATRAN, it is important to take TEVA-DABIGATRAN exactly as prescribed by your doctor.

In rare occasions, where you need emergency surgery or other urgent procedure or have obvious or hidden uncontrolled bleeding, you may have to discontinue taking TEVA-DABIGATRAN. In these situations, PRAXBIND (idarucizumab), a specific antidote for reversing the effect of TEVA-DABIGATRAN, can be used to immediately and completely reverse the blood-thinning effect of TEVA-DABIGATRAN.

Your doctor will tell you when it is appropriate for you to resume taking TEVA-DABIGATRAN.

BEFORE you use TEVA-DABIGATRAN talk to your doctor, nurse, or pharmacist if you:

  • Have moderately reduced kidney function.
  • Are dehydrated.
  • Have a disease or have had an operation recently that increases your risk of bleeding. Examples are a blood clotting disease, a stomach ulcer, a biopsy, a very serious injury, or an inflammation of parts of your heart caused by bacteria.
  • Are older than 75 years old.
  • Have severe or life-threatening liver disease, or high liver enzymes.
  • Are going to have a surgery, including a surgery on your brain, back, eye or other invasive or dental procedure. Your doctor may ask you to stop TEVA-DABIGATRAN temporarily for a few days before the surgery.
  • Are pregnant or plan to become pregnant. The effects of TEVA-DABIGATRAN on pregnancy and the unborn child are not known.
  • Are about to give birth.
  • Are less than 18 years old.
  • Weigh less than 50 kg.

    As with most medicines, interactions with other drugs are possible. Tell your doctor, nurse, or pharmacist about all medicines you take, including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines.

The following may interact with TEVA-DABIGATRAN:

  • Antacids, used to treat heartburns. If you need to take an antacid, take it at least two hours after taking TEVA-

    DABIGATRAN.

  • Antibiotics, including rifampicin and clarithromycin.
  • Antidepressants, in particular selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs).
  • Antifungal drugs, including oral itraconazole and posaconazole.
  • Antiretroviral drugs, used to treat HIV, including nelfinavir, ritonavir, saquinavir, and tipranavir.
  • Blood thinners, including clopidogrel, prasugrel
  • (EFFIENT) or ticagrelor (BRILINTA).
  • Drugs used to prevent organ rejection after transplantation, including cyclosporine and tacrolimus.
  • Drugs used to treat epilepsy, including carbamazepine
  • Drugs used to treat irregular heartbeats, including amiodarone (CORDARONE),
  • dronedarone (MULTAQ) and quinidine.

INTERACTIONS WITH THIS MEDICATION

  • Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and swelling.
  • Examples include aspirin (ASA), diclofenac,

    ibuprofen and naproxen.

    • Proton pump inhibitors, used to treat heartburns.
    • St. John’s Wort, an herbal medicine.
    • Verapamil, used to lower blood pressure.

      Know the medicines you take. Keep a list of them and show it to your doctor, dentist and pharmacist when you get a new medicine or whenever you seek medical treatment.

PROPER USE OF THIS MEDICATION

Before you start taking TEVA-DABIGATRAN and regularly

after, your doctor will test your kidney function.

Take TEVA-DABIGATRAN exactly as prescribed.

TEVA-DABIGATRAN should be taken with a full glass of water and can be taken with or without food. If TEVA-DABIGATRAN upsets your stomach, take it with meals or within 30 minutes after meals. If TEVA-DABIGATRAN still upsets your stomach, consult your physician or pharmacist. It is important to continue taking TEVA-DABIGATRAN as prescribed.

Swallow the capsule(s) whole. Do not chew or open the capsule. Do not sprinkle the pellets on food or mix with liquids.

Usual Adult dose:

If your doctor has given you TEVA-DABIGATRAN to take twice a day, it is important to take it regularly at the same time each day at approximately 12 hour intervals.

Depending on your kidney function or other drugs

you may be taking, your doctor may prescribe a lower dose of 150 mg once daily (taken as two capsules of 75 mg at the same time).

Take TEVA-DABIGATRAN for as long as the doctor tells you.

  • To treat blood clots and prevent them from re-occurring in the veins of your leg(s) or in your lung(s): 300 mg a day, taken as one (1) capsule of 150 mg twice daily.

You will start taking TEVA-DABIGATRAN following 5 to 10 days treatment with an injectable blood thinner.

The doctor will determine how long you should take

TEVA-DABIGATRAN so take it until your doctor tells you to stop.

  • For patients who have irregular heartbeats (atrial fibrillation): 300 mg a day, taken as one (1) capsule of 150 mg, twice daily.

Switching to TEVA-DABIGATRAN:

If you are currently taking the blood thinner

warfarin or receive a blood thinner given by injection, and your doctor has decided TEVA-DABIGATRAN is appropriate for you, make sure you ask your doctor when and how best to switch and start taking TEVA-DABIGATRAN.

Overdose:

If you think you have taken too much TEVA-DABIGATRAN, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

If you take more than the recommended dose of TEVA-DABIGATRAN, you may have an increased risk of bleeding. Your doctor

can perform a blood test to assess the risk of bleeding.

For situations when rapid reversal of the blood-thinning effect of TEVA-DABIGATRAN is required, PRAXBIND (idarucizumab), a specific antidote for reversing the effect of TEVA-DABIGATRAN, can be available in hospitals and emergency rooms.

Missed Dose:

For all treatments, if you forget to take TEVA-DABIGATRAN, do not take a double dose to make up for the missed dose.

  • After knee or hip replacement surgery: Take your next dose at the same time next day.
  • To treat blood clots and prevent them from re-occurring in the veins of your leg(s) or in your lung(s): Take it as soon as you remember, but if it is almost time for your next dose (less than 6 hours before your next dose), take your next dose when you are supposed to.
  • For patients who have irregular heartbeats (atrial fibrillation): Take it as soon as you remember, but if it is almost time for your next dose (less than 6 hours before your next dose), take your next dose when you are supposed to.

If you had knee or hip replacement surgery or are receiving treatment for prevention of blood clots in the veins of your legs and lungs and stop taking TEVA-DABIGATRAN before your doctor told you to, you are at risk of developing a blood clot in a vein of your leg or in the lungs, which can be life-threatening.

If you have atrial fibrillation and stop taking TEVA-DABIGATRAN without talking to your doctor, you are at risk of suffering from a stroke or other complications due to blood clot formation, which can be fatal or lead to severe disability.

You should be aware that prescription medicines carry some risks and that all possible risks may not be known at this stage.

As TEVA-DABIGATRAN acts on the blood clotting system, most side effects are related to signs of bruising or bleeding.

Although rare, TEVA-DABIGATRAN can cause very serious or severe bleeding that can occur in any part of your body. These bleeding may reduce your physical abilities or even lead to death.

Patients treated with TEVA-DABIGATRAN may experience the following side effects:

  • abdominal pain, diarrhea, heartburn, nausea, reflux of gastric juice, upset stomach, vomiting ;
  • difficulty swallowing;
  • bruising;
  • hives, itching, rash.

TEVA-DABIGATRAN can cause abnormal blood test results for kidney and liver function, number of platelets and number of red blood cells (anemia). Your doctor will ask for blood tests and will interpret the results.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom / effect

Talk with your

doctor or pharmacist

Stop taking drug and seek

immediate emergency medical attention

Only if severeIn all cases

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom / effect

Talk with your

doctor or pharmacist

Stop taking drug and seek

immediate emergency medical attention

Only if severeIn all cases
CommonAnemia: feeling tired and weak, pale skin, cold hands and feet✓
Bleeding from penis/vagina✓
Blood in the urine that stains it pink or red✓

Bleeding in the stomach or

bowel: darker stool (like tar), bright red blood in your toilet or toilet tissue, vomiting blood

✓
Bruising or bleeding due to injury or after operation✓

After surgery: Severe bleeding from

the surgical wound, an injury or other procedures

✓
After surgery: Liquid oozing from the surgical wound✓
Nose bleed✓
Bleeding under the skin✓
Uncomm on

Allergic reaction, including

angioedema:

rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing

✓

Decreased

platelets: bruising, bleeding, fatigue and weakness

✓
Coughing blood or blood stained sputum✓
SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect

Bleeding into a joint : pain,

swelling at a single spot on the knee, ankle or shoulder Bleeding into the rectum or

from

haemorrhoids

Bleeding from site of catheter

entry into vein

Bleeding into the brain:

headache,

difficulty seeing or speaking, lack of balance and

coordination,

weakness on one side, numbness

Inflammation of the stomach, esophagus

(food pipe):

difficult and/or painful

swallowing,

heartburn, mouth sores, feeling of something being stuck in the throat, nausea, vomiting

Talk with your

doctor or pharmacist

Stop taking drug and seek

immediate emergency medical attention

Only if severeIn all cases
✓
✓
✓
✓
✓

Liver disorder -

symptoms include nausea,

vomiting, loss of appetite combined with itching,

yellowing of the skin or eyes, dark urine

✓

This is not a complete list of side effects. For any unexpected effects while taking TEVA-DABIGATRAN, contact your doctor, nurse, or pharmacist immediately.

HOW TO STORE IT

Keep out of the reach and sight of children and pets. Do not use TEVA-DABIGATRAN after the expiry date printed on the carton or blister.

Store between 15 - 30°C. Store in the original package to protect from moisture.

When removing a capsule from the blister, please note the following instructions:

  • Tear off individual blister from the blister card along the perforated line;
  • Peel off the backing foil and remove the capsule;
  • The capsule should not be pushed through the blister foil;
  • Do not peel the blister foil until a capsule is required.

Do not put the capsules in pill boxes or pill organizers, unless capsules can be maintained in the original package. Any unused product or waste material should be disposed in accordance with local requirements.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting

    (http://www.hc-sc.gc.ca/dhp-mps/medeff/report-

    declaration/index-eng.php) for information on how to report online, by mail or by fax; or

  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need

information about how to manage your side effects. The

Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found by contacting Teva Canada Limited by:

Phone: 1-800-268-4127 ext. 3; Email: druginfo@tevacanada.com ; or Fax: 1-416-335-4472

30 Novopharm Court

Toronto, Ontario

Canada M1B 2K9

www.tevacanada.com

Prepared on: April 26, 2017

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02463458

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Teva-Dabigatran

Rx or OTC
Prescription (Rx)?
DIN 02463458, 02463466
Schedule(s) PRESCRIPTION
Active ingredient(s) Dabigatran etexilate (dabigatran etexilate mesilate)
Dosage form(s) Capsule
Route(s) of administration Oral
Drug class (WHO ATC)
  1. B Blood and blood forming organ drugs
    1. B01 Antithrombotic agents
      1. B01A Antithrombotic agents
        1. B01AE Direct thrombin inhibitors
          1. B01AE07 Dabigatran etexilate
Company TEVA CANADA LIMITED
Current status Cancelled Pre Market
Current status date July 30, 2026
Strengths and forms
DIN Strength Dosage form(s) Current status
02463458 75 MG Capsule Cancelled Pre Market July 30, 2026
02463466 150 MG Capsule Cancelled Pre Market July 30, 2026

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.